Bladder Squamous Cell Carcinoma
NCI Definition: A squamous cell carcinoma of the bladder arising from metaplastic epithelium. It represents less than 10% of bladder carcinomas. The exception is the Middle East along the Nile Valley, where it represents the most common form of carcinoma because of the endemic nature of schistosomiasis. Bladder squamous cell carcinoma is often associated with long-standing chronic inflammation of the bladder and usually has a poor prognosis. The diagnosis of squamous cell carcinoma of the bladder should be reserved for those tumors that are predominantly keratin forming. 
Bladder squamous cell carcinomas most frequently harbor alterations in TP53, KMT2D, CDKN2A, PIK3CA, and FBXW7 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, KMT2D Mutation, and PIK3CA Mutation are the most common alterations in bladder squamous cell carcinoma .
There are 5 clinical trials for bladder squamous cell carcinoma, of which 4 are open and 1 is completed or closed. Of the trials that contain bladder squamous cell carcinoma as an inclusion criterion, 1 is phase 1 (1 open) and 4 are phase 2 (3 open).
Ipilimumab, nivolumab, and cabozantinib are the most common interventions in bladder squamous cell carcinoma clinical trials.
Significant Genes in Bladder Squamous Cell Carcinoma
CD274 is an inclusion eligibility criterion in 1 clinical trial for bladder squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and bladder squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.